Evidence map›Paper›PMID 37582288›Full record

ArticleBlood advances2023

AML with complex karyotype: extreme genomic complexity revealed by combined long-read sequencing and Hi-C technology.

Marius-Konstantin Klever, Eric Sträng, Sara Hetzel, Julius Jungnitsch, Anna Dolnik, Robert Schöpflin, Jens-Florian Schrezenmeier, Felix Schick, Olga Blau, Jörg Westermann and 9 more

Open access · goldAbstract read
In one paragraph

Article in Blood advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Chromothripsis in myeloid malignancies.Annals of hematology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 6 institutions in 1 country.

Marius-Konstantin KleverDivision of Hematology, Oncology, and Cancer Immunology, Medical Department, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Eric SträngDivision of Hematology, Oncology, and Cancer Immunology, Medical Department, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Sara HetzelDepartment of Genome Regulation, Max Planck Institute for Molecular Genetics, Berlin, Germany.ORCID 0000-0002-4783-3814
Julius JungnitschInstitute for Medical Genetics and Human Genetics, Charité University Medicine Berlin, Berlin, Germany.
Anna DolnikDivision of Hematology, Oncology, and Cancer Immunology, Medical Department, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Robert SchöpflinRG Development and Disease, Max Planck Institute for Molecular Genetics, Berlin, Germany.
Jens-Florian SchrezenmeierDivision of Hematology, Oncology, and Cancer Immunology, Medical Department, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Felix SchickDivision of Hematology, Oncology, and Cancer Immunology, Medical Department, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Olga BlauDivision of Hematology, Oncology, and Cancer Immunology, Medical Department, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Jörg WestermannDivision of Hematology, Oncology, and Cancer Immunology, Medical Department, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Frank G RückerDepartment of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.
Zuyao XiaDepartment of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.
Konstanze DöhnerDepartment of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.
Hubert SchrezenmeierInstitute of Transfusion Medicine, University of Ulm, Ulm, Germany.
Malte SpielmannHuman Molecular Genomics Group, Max Planck Institute for Molecular Genetics, Berlin, Germany.ORCID 0000-0002-0583-4683
Alexander MeissnerDepartment of Genome Regulation, Max Planck Institute for Molecular Genetics, Berlin, Germany.ORCID 0000-0001-8646-7469
Uirá Souto MeloRG Development and Disease, Max Planck Institute for Molecular Genetics, Berlin, Germany.
Stefan MundlosRG Development and Disease, Max Planck Institute for Molecular Genetics, Berlin, Germany.
Lars BullingerDivision of Hematology, Oncology, and Cancer Immunology, Medical Department, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Humboldt-Universität zu Berlin · DEMax Planck Institute for Molecular Genetics · DEUniversity Hospital Ulm · DEGerman Cancer Research Center · DEUniversität Ulm · DEVivantes Klinikum · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute myeloid leukemia with complex karyotype (CK-AML) is associated with poor prognosis, which is only in part explained by underlying TP53 mutations. Especially in the presence of complex chromosomal rearrangements, such as chromothripsis, the outcome of CK-AML is dismal. However, this degree of complexity of genomic rearrangements contributes to the leukemogenic phenotype and treatment resistance of CK-AML remains largely unknown. Applying an integrative workflow for the detection of structural variants (SVs) based on Oxford Nanopore (ONT) genomic DNA long-read sequencing (gDNA-LRS) and high-throughput chromosome confirmation capture (Hi-C) in a well-defined cohort of CK-AML identified regions with an extreme density of SVs. These rearrangements consisted to a large degree of focal amplifications enriched in the proximity of mammalian-wide interspersed repeat elements, which often result in oncogenic fusion transcripts, such as USP7::MVD, or the deregulation of oncogenic driver genes as confirmed by RNA-seq and ONT direct complementary DNA sequencing. We termed this novel phenomenon chromocataclysm. Thus, our integrative SV detection workflow combing gDNA-LRS and Hi-C enables to unravel complex genomic rearrangements at a very high resolution in regions hard to analyze by conventional sequencing technology, thereby providing an important tool to identify novel important drivers underlying cancer with complex karyotypic changes.

Indexed as

Leukemia, Myeloid, AcuteAbnormal KaryotypeChromosome AberrationsGenomicsHumansMutationUbiquitin-Specific Peptidase 7Ubiquitin-Specific Peptidase 7USP7 protein, human

Identifiers

PMID37582288
PMCPMC10632680
OpenAlexW4385828859

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.